Talking Research event 2015 in Manchester

Sarcoma UK funds only high quality research to understand more about sarcoma, find new treatments and ultimately identify a cure. 

Here is a selection of papers, presentations and other outputs from some of the high quality research we have funded. Click on the titles for more detail on the individual projects.

Forshew: A blood test for sarcoma?

Poster presentations at Dublin Pathology Conference 2015

  • IDH1 and IDH2 digital PCR assay development for chondrosarcoma tissue and plasma analysis. Gutteridge, A. Rathbone, V.M. Gupta, M. Amary, M.F. Flanagan, A.M. Forshew, T.
  • Development of Diagnostic Test for H3F3A p.Gly34Try (G34W) Mutation in Giant Cell Tumours of Bone Based on Droplet Digital PCR. VM Rathbone, DJ Adams, A Gutteridge, R Tirabosco, MF Amary, T Forshew, AM Flanagan and M Gupta

Presentations

  • Sequencing and dPCR analysis of circulating tumour DNA. The challenges and potential applications of liquid biopsy analysis - New Zealand Next Generation Sequencing Conference. New Zealand. KEYNOTE SPEAKER
  • NGS and dPCR Analysis of Circulating Tumour DNA and Their Potential Uses in Cancer Patient Care. qPCR & NGS 2015 - Advanced Molecular Diagnostics for Biomarker Discovery.  Germany

Gerrand: Studying the impact of treatment on sarcoma survivors

Presentations

Harrington & Pencavel: Developing a preclinical and clinical system for oncolytic virotherapy using isolated limb perfusion 

Presentations

  • Development of an in vivo model of isolated limb perfusion for oncolytic viral therapy in advanced extremity sarcoma and melanoma.’ Pencavel T, Seth R, Hayes A, Harrington K. Imperial College Surgical Symposium, London 2009 – Awarded 2nd Prize.
  • ‘Oncolytic virotherapy in an in vivo model of Isolated Limb Perfusion for advanced extremity sarcoma.’ Pencavel T, Seth R, Hayes AJ, Harrington KJ. Imperial College Surgical Symposium, London 2010.
  • ‘Isolated Limb Perfusion and Viral Therapy: Precision Guidance for Paris’s Arrow?’ Pencavel T, Seth R, Hayes A, Harrington K. British Sarcoma Group Annual Conference, London 2010
  • Administration of Oncolytic Vaccinia Virus GLV1h68 by Isolated Limb Perfusion to an Immunocompetent Rat Model of Advanced Extremity Sarcoma.’ Pencavel T, Seth R, Khan AA, Mansfield D, Hayes AJ, Harrington KJ. European Multidisciplinary Cancer Congress, Stockholm, September 2011
  • ‘Oncolytic Virotherapy in an In Vivo model of Isolated Limb Perfusion for advanced extremity sarcoma.’ Pencavel T, Seth R, Hayes AJ, Harrington KJ. Society of Academic and Research Surgeons Annual Meeting, Dublin, January 2011
  • ‘Treatment with oncolytic viruses with TNF/melphalan isolated limb perfusion for extremity sarcoma and melanoma – preclinical models and clinical trials.’ (with M Wilkinson) Sarkomen Conference, Beromun Expert Meeting, Berlin, March 2012
  • The addition of oncolytic vaccinia virus to standard isolated limb perfusion chemotherapeutics delays tumour growth in a rat model of aggressive extremity sarcoma. Wilkinson MJ, Pencavel T, Khan AA, Mansfield DC, Kyula J, RoulstoneV, Yu YA, Szalay AA, Hayes AJ, Harrington KJ. September 2013, Amsterdam, European Cancer Congress

Publications

  • Locoregional intravascular viral therapy of cancer: precision guidance for Paris’s arrow? Pencavel T, Seth R, Hayes A, Melcher A, Pandha H, Vile R, Harrington KJ. Gene Ther 2010 Aug;17(8):949-60
  • Published in the Annals of Surgery ANNSURG-D-12-01724 
  • Isolated limb perfusion with melphalan, tumour necrosis factoralpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma Tim D Pencavela,b*, Michelle J Wilkinsona,b*, David C Mansfielda, Aadil A Khana, Rohit Setha, Eleni M Karapanagiotoua, Victoria Roulstonea, Richard J Aguilarc, Nanhai G Chenc,e, Aladar A Szalayc,d,e, Andrew J Hayesb, Kevin J Harrington International Journal of Cancer 02/2015; 136(4)

Other

Huang: Dissecting the mechanisms of pazopanib in soft tissue sarcoma

Presentations

  • Sarcoma UK Talking Research event June 2015

Other

  • Mutations identified in this work are found in ~20% of cancers.  Based on our results, we have applied for a grant to look at drug targets lung cancer. We have received funding of £50,000 from the Lung Cancer Research Foundation in Oct 2015 to pursue this follow-on work.

Hupp: Looking for new targeted treatments for high grade sarcoma

Presentations

Publications

Riley, Smith & Judson: A prospective observational study to evaluate the quality of life of patients with locally advanced and metastatic soft tissue sarcoma

Presentations

  • Advanced Soft tissue sarcoma: A retrospective evaluation of symptoms, palliative care involvement and overall survival in a sarcoma unit.  Gough N, Smith C, Ross JR, Riley J, Judson I. Poster Presentation: European Association of Palliative Care Congress: Lisbon, May 2011
  • A prognostic score to guide appropriate delivery of first line palliative chemotherapy for advanced soft tissue sarcoma. Gough N, Smith C, Ross JR, Riley J, Judson I. Accepted for poster presentation: European Society of Medical Oncology (ESMO) conference, Vienna, September 2012
  • Presentation at British Sarcoma Group  2014 Royal Marsden Prospective QoL study

Publications

  • Symptom burden, survival and palliative care in advanced soft tissue sarcoma 
  • Gough N, Smith C, Ross JR, Riley J, Judson I.  Journal Article: Sarcoma. 2011; 325189. Epub 2011 Dec 11 

Sisley, Salawu & Robinson: Defects of DNA repair genes and cell cycle regulators as a predisposing cause of Sarcomas

Presentations

Other 

  • PhD thesis for Dr Azeez Salawu

Veal: Study to investigate correlations between age-dependant pharmacokinetic variation, side effects of chemotherapy and biomarkers of toxicity in Ewing’s sarcoma

Presentations to date

Other

  • 38 patients recruited during year 1 of project at 16 UK sites

Wackerhage: Investigating Rhabdomyosarcoma & Causes and therapeutic implications of YAP activity in embryonal rhabdomyosarcoma

Presentations

  • When Hippo met MCAT: How Hippo links to stem cells, cancer and dystrophy in skeletal muscle. Presented February 2014 at St. Andrews Cancer Colloqium:
  • The Role of the Hippo Pathway in Rhabdomyosarcoma at the Scottish Sarcoma Network meeting, Dundee, May 2015, to a meeting of Scottish Sarcoma clinicians.
  • Taz and Yap in rhabdomyosarcoma: agonists or antagonists? In July 2014 at the Zurich Rhabdomyosarcoma meeting
  • Persistent YAP hyperactivity drives CINSARC gene expression and results in tumours with complex genomes at the Keystone Hippo meeting, Taos, May 2015

Publications

  • The Hippo signal transduction network in skeletal and cardiac muscle. Henning Wackerhage, Dominic P. Del Re, Robert N. Judson, Marius Sudol, Junichi Sadoshima. Science Signaling 7 (337), re4. 
  • Tremblay, A.M., Missiaglia, E., Galli, G.G., Hettmer, S., Urcia, R., Carrara, M., Judson, R.N., Thway, K., Nadal, G., Selfe, J.L., et al. (2014). The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation. Cancer Cell 26, 273-287. 
  • Mohamed, A.D., Tremblay, A.M., Murray, G.I., and Wackerhage, H. (2015). The Hippo signal transduction pathway in soft tissue sarcomas. BBA cancer, epub http://www.ncbi.nlm.nih.gov/pubmed/26050962

Further funding

  • 2014 Friends of Anchor. Wackerhage H, Stevenson D, Turbitt J, Urcia R: Does the Yap oncogene worsen cancer by inducing chromosomal instability and oncogene copy number gains? £9,870 (04.2012 Dr Henning Wackerhage) 
  • 2014 Friends of Anchor. Wackerhage H, Collie-Duguid E, Murray G, and Urcia R: Yap, Taz, and Vgll3: How does this trio drive tumourigenesis in two types of rhabdomyosarcoma? £9,200 (04.2012 Dr Henning Wackerhage)

Young: Studies in angiosarcoma using canine tumours 

Presentations

Publications

  • Young RJ, Flewers T, Staton CA, Woll PJ, Reed MWR, Brown NJ. Canine Angiosarcoma: A tumour model. 64th Annual British Microcirculation Society Meeting. Bristol, UK. 2014. Poster presentation.